Virotherapy: Cancer gene therapy at last?.

F1000Research

Volumn 5, Issue , 2016, Pages

  Bilsland, Alan E ^a   Spiliopoulou, Pavlina ^b   Jeffry Evans, T R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNX 2401; G 207; HERPESVIRUS VECTOR; NTX 010; ONCOLYTIC VIRUS; ONCOS 102; PELAREOREP; UNCLASSIFIED DRUG;

CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; GLIOMA; HUMAN; IMMUNOMODULATION; MESOTHELIOMA; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; TUMOR IMMUNITY; UTERINE TUBE TUMOR; VIRUS ENTRY; VIRUS REPLICATION;

EID: 85010871791     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.8211.1     Document Type: Review

References (102)

1. Chira S, Jackson CS, Oprea I, et al.: Progresses towards safe and efficient gene therapy vectors. Oncotarget. 2015; 6(31): 30675-703.
2. Clayman GL, el-Naggar AK, Roth JA, et al.: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 1995; 55(1): 1-6.
3. Fujiwara T, Grimm EA, Mukhopadhyay T, et al.: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wildtype p53 gene. Cancer Res. 1994; 54(9): 2287-91.
4. Kim J, Hwang ES, Kim JS, et al.: Intraperitoneal gene therapy with adenoviralmediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. Cancer Gene Ther. 1999; 6(2): 172-8.
5. Pagliaro LC, Keyhani A, Liu B, et al.: Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol. 2003; 21(6): 456-62.
6. Spitz FR, Nguyen D, Skibber JM, et al.: In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 1996; 16(6B): 3415-22.
7. Merdan T, Kopecek J, Kissel T: Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev. 2002; 54(5): 715-58.
8. Moreno PM, Pêgo AP: Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem. 2014; 2: 87.
9. Keith WN, Bilsland A, Hardie M, et al.: Drug insight: Cancer cell immortalitytelomerase as a target for novel cancer gene therapies. Nat Clin Pract Oncol. 2004; 1(2): 88-96.
10. Das SK, Menezes ME, Bhatia S, et al.: Gene Therapies for Cancer: Strategies, Challenges and Successes. J Cell Physiol. 2015; 230(2): 259-71.
11. Chen GX, Zhang S, He XH, et al.: Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. Onco Targets Ther. 2014; 7: 1901-9.
12. Kastelein JJ, Ross CJ, Hayden MR: From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world. Hum Gene Ther. 2013; 24(5): 472-8.
13. Dock G: The Influence of complicating diseases upon leukÆmia. The American Journal of the Medical Sciences. 1904; 127(4): 563-92.
14. Kelly E, Russell SJ: History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007; 15(4): 651-9.
15. Southam CM: Present status of oncolytic virus studies. Trans N Y Acad Sci. 1960; 22(8 Series II): 657-73.
16. Oldfield EH, Ram Z, Culver KW, et al.: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther. 1993; 4(1): 39-69.
17. Crystal RG: Adenovirus: the first effective in vivo gene delivery vector. Hum Gene Ther. 2014; 25(1): 3-11.
18. Glorioso JC: Herpes simplex viral vectors: late bloomers with big potential. Hum Gene Ther. 2014; 25(2): 83-91.
19. Miller AD: Retroviral vectors: from cancer viruses to therapeutic tools. Hum Gene Ther. 2014; 25(12): 989-94.
20. Mulligan RC: Development of gene transfer technology. Hum Gene Ther. 2014; 25(12): 995-1002.
21. Rots MG, Elferink MG, Gommans WM, et al.: An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents. J Gene Med. 2006; 8(1): 35-41.
22. Liu BL, Robinson M, Han Z, et al.: ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10(4): 292-303.
23. Hirvinen M, Heiskanen R, Oksanen M, et al.: Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. J Transl Med. 2013; 11: 193.
24. Kanerva A, Nokisalmi P, Diaconu I, et al.: Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013; 19(10): 2734-44.
25. Pesonen S, Diaconu I, Kangasniemi L, et al.: Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012; 72(7): 1621-31.
26. Taipale K, Liikanen I, Juhila J, et al.: Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Mol Ther. 2016; 24(1): 175-83.
27. Angelova AL, Geletneky K, Nuesch JP, et al.: Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients. Front Bioeng Biotechnol. 2015; 3: 55.
28. Kemp V, Hoeben RC, van den Wollenberg DJ: Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus. Viruses. 2016; 8(1): pii: E4.
29. Al Yaghchi C, Zhang Z, Alusi G, et al.: Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy. 2015; 7(12): 1249-58.
30. Dorer DE, Nettelbeck DM: Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev. 2009; 61(7-8): 554-71.
31. Berk AJ: Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene. 2005; 24(52): 7673-85.
32. Flint J, Shenk T: Viral transactivating proteins. Annu Rev Genet. 1997; 31: 177-212.
33. Barker DD, Berk AJ: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology. 1987; 156(1): 107-21.
34. Bischoff JR, Kirn DH, Williams A, et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996; 274(5286): 373-6.
35. O'Shea CC, Soria C, Bagus B, et al.: Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell. 2005; 8(1): 61-74.
36. Galanis E, Okuno SH, Nascimento AG, et al.: Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 2005; 12(5): 437-45.
37. Habib N, Salama H, Abd El Latif Abu Median A, et al.: Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 2002; 9(3): 254-9.
38. Habib NA, Sarraf CE, Mitry RR, et al.: E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther. 2001; 12(3): 219-26.
39. Khuri FR, Nemunaitis J, Ganly I, et al.: a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000; 6(8): 879-85.
40. Makower D, Rozenblit A, Kaufman H, et al.: Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res. 2003; 9(2): 693-702.
41. Reid T, Galanis E, Abbruzzese J, et al.: Hepatic arterial infusion of a replicationselective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002; 62(21): 6070-9.
42. Reid TR, Freeman S, Post L, et al.: Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 2005; 12(8): 673-81.
43. Fueyo J, Gomez-Manzano C, Alemany R, et al.: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000; 19(1): 2-12.
44. Suzuki K, Fueyo J, Krasnykh V, et al.: A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res. 2001; 7(1): 120-6.
45. Bergelson JM, Cunningham JA, Droguett G, et al.: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997; 275(5304): 1320-3.
46. Kirby I, Davison E, Beavil AJ, et al.: Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J Virol. 1999; 73(11): 9508-14.
47. Roelvink PW, Mi Lee G, Einfeld DA, et al.: Identification of a conserved receptorbinding site on the fiber proteins of CAR-recognizing adenoviridae. Science. 1999; 286(5444): 1568-71.
48. Wang K, Huang S, Kapoor-Munshi A, et al.: Adenovirus internalization and infection require dynamin. J Virol. 1998; 72(4): 3455-8.
49. Wickham TJ, Mathias P, Cheresh DA, et al.: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993; 73(2): 309-19.
50. Cohen CJ, Shieh JT, Pickles RJ, et al.: The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci U S A. 2001; 98(26): 15191-6.
51. Hamdan S, Verbeke CS, Fox N, et al.: The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gene transfer in pancreatic cancer cells. Cancer Gene Ther. 2011; 18(7): 478-88.
52. Strauss R, Sova P, Liu Y, et al.: Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res. 2009; 69(12): 5115-25.
53. Wang H, Li ZY, Liu Y, et al.: Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011; 17(1): 96-104.
54. Kanerva A, Zinn KR, Chaudhuri TR, et al.: Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther. 2003; 8(3): 449-58.
55. Cerullo V, Pesonen S, Diaconu I, et al.: Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010; 70(11): 4297-309.
56. Hemminki O, Parviainen S, Juhila J, et al.: Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy. Oncotarget. 2015; 6(6): 4467-81.
57. Cascallo M, Alonso MM, Rojas JJ, et al.: Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther. 2007; 15(9): 1607-15.
58. Kuhn I, Harden P, Bauzon M, et al.: Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 2008; 3(6): e2409.
59. Fishelson Z, Donin N, Zell S, et al.: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol. 2003; 40(2-4): 109-23.
60. Segerman A, Atkinson JP, Marttila M, et al.: Adenovirus type 11 uses CD46 as a cellular receptor. J Virol. 2003; 77(17): 9183-91.
61. MacLean AR, ul-Fareed M, Robertson L, et al.: Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol. 1991; 72(Pt 3): 631-9.
62. Brown SM, Harland J, MacLean AR, et al.: Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J Gen Virol. 1994; 75(Pt 9): 2367-77.
63. Kesari S, Randazzo BP, Valyi-Nagy T, et al.: Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest. 1995; 73(5): 636-48.
64. Papanastassiou V, Rampling R, Fraser M, et al.: The potential for efficacy of the modified (ICP 34.5-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 2002; 9(6): 398-406.
65. Rampling R, Cruickshank G, Papanastassiou V, et al.: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 2000; 7(10): 859-66.
66. Harrow S, Papanastassiou V, Harland J, et al.: HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 2004; 11(22): 1648-58.
67. Mineta T, Rabkin SD, Yazaki T, et al.: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995; 1(9): 938-43.
68. Markert JM, Medlock MD, Rabkin SD, et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000; 7(10): 867-74.
69. Markert JM, Liechty PG, Wang W, et al.: Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2009; 17(1): 199-207.
70. Markert JM, Razdan SN, Kuo HC, et al.: A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014; 22(5): 1048-55.
71. Goldsmith K, Chen W, Johnson DC, et al.: Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response. J Exp Med. 1998; 187(3): 341-8.
72. Andtbacka RH, Kaufman HL, Collichio F, et al.: Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25): 2780-8.
73. Duad A, Ribas A, Robert C, et al.: Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol. 2015; 33(suppl): Abstract 9005.
74. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8): 711-23.
75. Kaufman HL, Ruby CE, Hughes T, et al.: Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014; 2: 11.
76. Greig SL: Talimogene Laherparepvec: First Global Approval. Drugs. 2016; 76(1): 147-54.
77. Puzanov I, Milhem MM, Minor D, et al.: Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016; 34(22): 2619-26.
78. Vinay DS, Ryan EP, Pawelec G, et al.: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35(Suppl): S185-98.
79. Kawakami Y, Robbins PF, Rosenberg SA: Human melanoma antigens recognized by T lymphocytes. Keio J Med. 1996; 45(2): 100-8.
80. Vandenberk L, Belmans J, Van Woensel M, et al.: Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. Front Immunol. 2015; 6: 663.
81. Middleton G, Silcocks P, Cox T, et al.: Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014; 15(8): 829-40.
82. Parry RV, Chemnitz JM, Frauwirth KA, et al.: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005; 25(21): 9543-53.
83. Maus MV, Grupp SA, Porter DL, et al.: Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014; 123(17): 2625-35.
84. Brentjens RJ, Rivière I, Park JH, et al.: Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118(18): 4817-28.
85. Kalos M, Levine BL, Porter DL, et al.: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3(95): 95ra73.
86. Kochenderfer JN, Dudley ME, Feldman SA, et al.: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119(12): 2709-20.
87. Porter DL, Levine BL, Kalos M, et al.: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8): 725-33.
88. Mato A, Porter DL: A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. Blood. 2015; 126(4): 478-85.
89. Kakarla S, Gottschalk S: CAR T cells for solid tumors: armed and ready to go? Cancer J. 2014; 20(2): 151-5.
90. VanSeggelen H, Hammill JA, Dvorkin-Gheva A, et al.: T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice. Mol Ther. 2015; 23(10): 1600-10.
91. Schmidt MR, Piekos B, Cabatingan MS, et al.: Expression of a human coxsackie/adenovirus receptor transgene permits adenovirus infection of primary lymphocytes. J Immunol. 2000; 165(7): 4112-9.
92. Nishio N, Diaconu I, Liu H, et al.: Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014; 74(18): 5195-205.
93. Melchiorri D, Pani L, Gasparini P, et al.: Regulatory evaluation of Glybera in Europe-two committees, one mission. Nat Rev Drug Discov. 2013; 12(9): 719.
94. Narayanan G, Cossu G, Galli MC, et al.: Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union. Hum Gene Ther Clin Dev. 2014; 25(1): 1-6.
95. Watanabe N, Yano K, Tsuyuki K, et al.: Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera. Mol Ther Methods Clin Dev. 2015; 2: 14066.
96. Ylä-Herttuala S: Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012; 20(10): 1831-2.
97. Harmonisation ICo: General principles to address virus and vector shedding ICH Considerations. 2009.
98. Harmonisation ICo: Oncolytic viruses ICH Considerations. 2009.
99. Cheever TR, Berkley D, Braun S, et al.: Perspectives on best practices for gene therapy programs. Hum Gene Ther. 2015; 26(3): 127-33.
100. Evans TR, Keith WN: Intra-peritoneal administration of genetic therapies: promises and pitfalls. Minerva Ginecol. 2004; 56(6): 529-38.
101. Merten OW, Schweizer M, Chahal P, et al.: Manufacturing of viral vectors for gene therapy: Part I. Upstream processing. Pharm Bioprocess. 2014; 2(2): 183-203.
102. DiMasi JA, Reichert JM, Feldman L, et al.: Clinical approval success rates for investigational cancer drugs. Clin Pharmacol Ther. 2013; 94(3): 329-35.